Pathogenic variants in high-penetrance genes such as BRCA2 (strongly associated with both breast and pancreatic cancer), PALB2 (a functional partner of BRCA2), and TP53 (linked to Li-Fraumeni syndrome) were considered primary candidates (18–20). This evidence concerns the gene BRCA2 and Li-Fraumeni syndrome.